Low‐dose tipifarnib is a promising treatment to control GC with an aggressive phenotype that exhibits high HIF‐1α expression by regulating Rheb farnesylation, mTOR/HIF‐1α signaling, and ROS levels. Here, MTOR is linked to gastric cancer.